Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off-Reference-Cited by-同舟云学术

Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off

Published:2017-09-09 Issue:10 Volume:108 Page:2045-2051
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Li Jin¹^ORCID,Xu Ruihua²,Xu Jianming³,Denda Tadamichi⁴,Ikejiri Koji⁵,Shen Lin⁶,Toh Yasushi⁷,Shimada Ken⁸,Kato Takeshi⁹,Sakai Kenji¹⁰,Yamamoto Manabu¹¹,Mishima Hideyuki¹²,Wang Jinwan¹³,Baba Hideo¹⁴

Affiliation:

1. Department of Oncology Fudan University Shanghai Cancer Center ShanghaiChina

2. Division of Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong ProvinceChina

3. No. 4 Division of Oncology People's Liberation Army No. 307 Hospital Beijing China

4. Division of Gastroenterology Chiba Cancer Center Chiba City Japan

5. Department of Surgery Gastroenterology Center National Hospital Organization Kyushu Medical Center Fukuoka City Japan

6. Digestive System Medicine Department Beijing Cancer Hospital Beijing China

7. Department of Gastroenterological Surgery National Hospital Organization National Kyushu Cancer Center Fukuoka City Japan

8. Department of Internal Medicine Showa University Northern Yokohama Hospital Yokohama City Japan

9. Department of Surgery Minoh City Hospital Minoh City Japan

10. Department of Medical Oncology Saiseikai Kumamoto Hospital Kumamoto City Japan

11. Department of Surgery Hiroshima Red Cross Hospital & Atomic‐bomb Survivors Hospital Hiroshima City Japan

12. Department of Surgery National Hospital Organization Osaka National Hospital Osaka City Japan

13. Division of Oncology Chinese Institute & Hospital Chinese Academy of Medical Sciences Beijing China

14. Gastroenterological Surgery Kumamoto University Hospital Kumamoto City Japan

Funder

Taiho Pharmaceutical

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13335

Reference24 articles.

1. International Agency for Research on Cancer World Health Organization.GLOBOCAN 2012: Estimated cancer incidence mortality and prevalence worldwide in 2012. [Cited 01 Mar 2017.] Available from URL:http://globocan.iarc.fr/

2. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

3. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis

4. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

5. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan;PLOS ONE;2020-12-29

2. Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer;The Oncologist;2020-06-17

3. Colorectal cancer: pharmacogenetics support for the correct drug prescription;Pharmacogenomics;2019-07

4. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial);European Journal of Cancer;2019-01

5. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients;DRUG DES DEV THER;2019